Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 15 posts of 146 posts found.

NICE approves first treatment for obstructive HCM for NHS use

June 2, 2023
Medical Communications Bristol-Myers Squibb, Cardiology, NHS, NICE, obstructive HCM

The National Institute for Health and Care Excellence (NICE) has announced that it has approved mavacamten (Camzyos) for the treatment …

News
Bristol Myers Squibb building in New Jersey

Bristol Myers Squibb psoriasis drug shows positive Phase III results

April 29, 2021
Bristol-Myers Squibb, bristol myers squibb, pharma, pharma news, psoriasis, psoriasis treatment

Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown positive results in two Phase …

News

Molecular Templates signs cancer deal with BMS worth up to $1.3bn

February 15, 2021
Sales and Marketing Bristol-Myers Squibb, bristol myers squibb

Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth up to $1.3 billion, to …

News
opdivo_1_1

NICE recommends Bristol Myers Squibb’s skin cancer drug Opdivo for NHS use

February 12, 2021
Medical Communications Bristol-Myers Squibb, NICE, bristol myers squibb

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

News
fda2outsideweb

Opdivo/Yervoy combo secures FDA approval for malignant pleural mesothelioma

October 6, 2020
Manufacturing and Production, Research and Development Bristol-Myers Squibb, Yervoy, bristol myers squibb, opdivo

Bristol Myers Squibb’s therapy regimen of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) has secured FDA approval for the first-line …

News
bristol_myers_squibb

Bristol Myers Squibb announces positive results from Opdivo clinical trials

August 12, 2020
Research and Development Bristol-Myers Squibb, Cancer, bristol myers squibb

Bristol Myers Squibb has announced positive data from two Phase 3 clinical trials of its drug Opdivo. The first trial …

News
bmssyracuseny

BMS’ Zeposia becomes first S1P receptor modulator available in Europe for relapsing remitting multiple sclerosis

May 28, 2020
Sales and Marketing Avonex, Bristol-Myers Squibb, EU, Europe, Zeposia, bristol myers squibb, multiple sclerosis

Bristol Myers Squibb is celebrating after its oral therapy Zeposia (ozanimod), secured European Commission for the treatment of relapsing remitting …

News
800px-european_commission_flags

Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations

May 1, 2020
Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …

News
bristolll

Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

April 21, 2020
Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb

Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …

News
bristolll

Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

April 14, 2020
Manufacturing and Production Bristol-Myers Squibb, Gilead, bristol myers squibb

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company’s …

News
000_britsol

FDA approves BMS’ Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

March 26, 2020
Sales and Marketing Bristol-Myers Squibb, COVID-19, Zeposia, coronavirus, multiple sclerosis, pharma

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but …

News
shutter

COVID-19: Gilead freezes compassionate access to remdesivir due to “overwhelming demand”, BMS and Lilly delay new study launches

March 24, 2020
Manufacturing and Production, Medical Communications, Research and Development Bristol-Myers Squibb, Eli Lilly, Gilead, Roche, cornavirus, pharma

As national governments continue to ramp up measures to contain the ongoing COVID-19 coronavirus outbreak, so too are pharma and …

News
shutterstock_212432119

Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer

February 19, 2020
Research and Development Bristol-Myers Squibb, Five Prime Therapeutics, Pancreatic cancer, cabiralizumab, opdivo, pharma

Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial investigating the efficacy of the former’s …

News

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019
Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …

News
shutterstock_138095450

Keytruda overtakes Opdivo to lead sales in global immune checkpoint inhibitor market, report reveals

November 19, 2019
Manufacturing and Production, Sales and Marketing Bristol-Myers Squibb, MSD, keytruda, opdivo, pharma

MSD’s Keytruda (pembrolizumab) overtook Bristol-Myers Squibb’s (BMS) blockbuster drug Opdivo (nivolumab) in total sales in the third quarter of 2019 …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023